Praxis reports Q2 2024 net loss $32.7M; cash $433.8M; multiple trial milestones on track

Praxis Precision Medicines, Inc.

2024-Q2 EPS reported -$4.41 revenue$788,000

Cash and investments $433.8M ($81.3M at Dec 31, 2023); runway into 2027.
Net loss $32.7M vs $34.3M YoY; R&D expense $27.3M vs $25.6M.
Ulixacaltamide Essential3 interim analysis in Q4 2024; NDA submission on track for 2025.
Relutrigine (PRAX-562) Phase 2 EMBOLD topline results expected Q3 2024.
PRAX-628 Phase 2/3 POWER1 study to start Q4 2024; RADIANT Phase 2 topline H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.